The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, raised $191 million by offering 11.3 million ADSs at $17, the high end of the range of $15 to $17. The company offered 1.9 million more ADSs than...read more
Updated Monday, 3/15. The IPO market starts to pick back up with 10 IPOs scheduled to raise $2.5 billion in the week ahead. Chinese IoT platform developer Tuya (TUYA) plans to raise $806 million at a $10.4 billion market...read more
Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, announced terms for its IPO on Friday. The Taicang, China-based company plans to raise $150 million by offering 9.4 million ADSs at a price...read more
US IPO Weekly Recap: The IPO market heats up in an 11 IPO week
The IPO market stayed busy this past week, with 11 IPOs raising $3.0 billion. The week’s IPOs were joined by 24 SPACs that raised $8.4 billion. New filers continued to fill the IPO pipeline, with 8 IPOs and 46 SPACs submitting initial filings. ...read more
Chinese inflammatory disease biotech Connect Biopharma prices upsized US IPO at $17 high end
Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, raised $191 million by offering 11.3 million ADSs at $17, the high end of the range of $15 to $17. The company offered 1.9 million more ADSs than...read more
US IPO Week Ahead: The spring IPO Market starts to thaw in a 10 IPO week
Updated Monday, 3/15. The IPO market starts to pick back up with 10 IPOs scheduled to raise $2.5 billion in the week ahead. Chinese IoT platform developer Tuya (TUYA) plans to raise $806 million at a $10.4 billion market...read more
Chinese inflammatory disease biotech Connect Biopharma sets terms for $150 million US IPO
Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, announced terms for its IPO on Friday. The Taicang, China-based company plans to raise $150 million by offering 9.4 million ADSs at a price...read more